Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography

Hepatology

Volumn 28, Issue 3, 1998, Pages 700-706

  Keiding, Susanne ^a   Hansen, Søren B ^a   Rasmussen, Henrik Højgaard ^a,b   Gee, Antony ^a   Kruse, Aksel ^a   Roelsgaard, Klaus ^a   Tage Jensen, Ulrik ^b   Dahlerup, Jens Frederik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0031752622     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510280316     Document Type: Article

References (27)

1. Broomé U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
2. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. HEPATOLOGY 1995;22:1404-1408.
3. Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995;117:146-155.
4. Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kolmannskog E Risk factors in primary sclerosing cholangitis. J Hepatol 1994;21:1061-1066.
5. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangilis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655-664.
6. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NE Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-25.
7. Wiesner RH, Porayko MK, Dickson ER, Gores GJ, LaRusso NF, Hay JE, Wahlstrōm HE, et al. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. HEPATOLOGY 1992;16:1290-1299.
8. Nashan B, Schlitt HJ, Tusch G, Oldhafer KJ, Ringe B, Wagner S, Pichlmayr R. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. HEPATOLOGY 1996;23:1105-1111.
9. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993;68:874-879.
10. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-355.
11. Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. HEPATOLOGY 1995;22:451-457.
12. Abu-Elmagd KM, Selby R, Iwatsuki S, Fung J, Tzakis A, Todo S, Demetris AJ, et al. Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect on survival after liver transplantation. Transpl Proc 1993;25:1124-1125.
13. Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 1991;32:1369-1373.
14. Warburg O. On the origin of cancer cells. Science 1965;123:309-314.
15. 18F)-flouro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771-777.
16. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703-707.
17. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, Hayashi H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
18. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997;32: 604-610.
19. Ludwig J, LaRusso NF, Wiesner RH. The syndrome of primary sclerosing cholangitis. Prog Liver Dis 1990;9:555-566.
20. Gjedde A. High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 1981;36:1463-1471.
21. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res Rev 1982;4:237-274.
22. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cerebral Blood Flow Metabol 1983;3:1-7.
23. Bland M. An Introduction to Medical Statistics. Oxford: Oxford University Press, 1995.
24. Choi Y, Hawkins RA, Huang S-C, Brunken RC, Hoh CK, Messa C, Nitzsche EU, et al. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver. J Nucl Med 1994;35:818-823.
25. Gjedde A, Wienhard K, Heiss W-D, Kloster G, Diemer NH, Herholz K, Pawlik G. Comparative regional analysis of 2-fluorodeoxyglycose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant. J Cereb Flow Metab 1985;5:163-178.
26. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
27. Dimitrakopoulou-Strauss A, Gutzler F, Strauss LG, Imgartinger G, Oberdorfer F, Doll J, Streramel W, et al. PET-Studien mit C-11-Athanol bei der intramuralen Therapie von hepatozellularen Karzinomen. Radiologe 1996;36:744-749.